Cost of revenue · 2016–2025
Neurocrine Biosciences cost of revenue
$52.1M+53.2% · FY2025
Neurocrine Biosciences (NBIX) reported $52.1M in cost of revenue for fiscal 2025, +53.2% year on year.
| Fiscal year | Cost of revenue | Change | Filing |
|---|---|---|---|
| FY20252025-12-31 | $52.1M | +53.2% | Open → |
| FY20242024-12-31 | $34.0M | −14.4% | Open → |
| FY20232023-12-31 | $39.7M | +71.1% | Open → |
| FY20222022-12-31 | $23.2M | +62.2% | Open → |
| FY20212021-12-31 | $14.3M | +41.6% | Open → |
| FY20202020-12-31 | $10.1M | +106.6% | Open → |
| FY20182018-12-31 | $4.9M | +289.9% | Open → |
| FY20172017-12-31 | $1.3M | +$1.3M | Open → |
| FY20162016-12-31 | $0 | — | Open → |
Cost of revenue — Cost of revenue is the direct cost of producing what the company sold — materials, manufacturing and the labour tied to delivery. It excludes sales, marketing and administration. Revenue minus this figure is gross profit.
Every row links to its own SEC filing · Fiscal year 2025 · Data as of September 25, 2026
Cost of revenue at companies of similar size
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Neurocrine Biosciences cost of revenue |url=https://companiesranked.com/en/company/neurocrine-biosciences/cost-of-revenue |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Neurocrine Biosciences cost of revenue. CompaniesRanked. https://companiesranked.com/en/company/neurocrine-biosciences/cost-of-revenueBibTeX
@misc{companiesranked-en-company-neurocrine-biosciences-cost-of-revenue-2026,
author = {{CompaniesRanked}},
title = {{Neurocrine Biosciences cost of revenue}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/neurocrine-biosciences/cost-of-revenue}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0000914475-26-000007 · February 11, 2026
{{cite web |title=Neurocrine Biosciences cost of revenue — 10-K (0000914475-26-000007) |url=https://www.sec.gov/Archives/edgar/data/914475/000091447526000007/nbix-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-11}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.